Ironwood Pharmaceuticals, Inc. - Class A Common Stock (IRWD)

Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.

IRWD stock results show that Ironwood Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.

IRWD stock results show that Ironwood Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

Here are the top movers in Thursday's session, showcasing the stocks with significant price changes.

Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements.

Let's delve into the US markets on Thursday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.

As the stock market corrects, focusing on stable investments is crucial. This is why you should steer clear of these biotech stocks to avoid.

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

The biotech industry offers investors unique investment opportunities but these three are biotechs to sell.

In what appears to be a theme this week, stocks are hesitant midday as investors unpack this morning's jobs and inflation data.

Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter financial results.

Ironwood Pharmaceuticals' SBS-IF treatment Apraglutide's Phase 3 trial met primary endpoints, reducing PS dependency by 25.5% vs. placebo, but misses on two key secondary endpoints.

U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining around 100 points on Thursday. Following the market opening Thursday, the Dow traded down 0.07% to 38,923.11 while the NASDAQ rose 0.65% to 16,051.57. The S&P 500 also rose, gaining, 0.30% to 5,084.74.

Polestar stock is rising higher on Thursday as holders of PSNY shares react to an update for the company's Chinese joint venture.

The company still plans to ask for approval of its short bowel syndrome treatment.

Tech stocks drive pre-market surge, Fed inflation data fails to disrupt rate cut expectations. Futures up for Nasdaq, S&P 500, and small caps.

Ironwood Pharmaceuticals stock is falling on Thursday with investors in IRWD unimpressed by its latest Phase III clinical trial results.

It's time to dive into the biggest pre-market stock movers for Thursday as we check out all of the news affecting shares this morning!